<DOC>
	<DOCNO>NCT02122952</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy intravenous delivery AVXS-101 treatment Spinal Muscular Atrophy type 1 ( SMN1 ) .</brief_summary>
	<brief_title>Gene Transfer Clinical Trial Spinal Muscular Atrophy Type 1</brief_title>
	<detailed_description>The study evaluate safety efficacy gene transfer Spinal Muscular Atrophy Type 1 ( SMA1 ) patient . SMA cause low level survival motor neuron ( SMN ) protein , affect muscle body . There effective treatment SMA current drug therapy unsuccessful stabilize reverse disease . Only supportive care currently possible . Open-label , dose-escalation clinical trial AVXS-101 inject intravenously peripheral limb vein . Short-term safety evaluate two year period . Patients test baseline return follow visit day 7 , 14 , 21 , 30 , follow every month 12 month post dose , every three month two ( 2 ) year post infusion . Unscheduled visit may occur PI determines necessary . The primary analysis efficacy assess patient reach 13.6 month age ( database lock perform time point patient reach 13.6 month age ) . A follow-up safety analysis complete time point last patient reach 24 month post-dose . Upon completion 2-year study period , patient monitor annually per standard care 15 year .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Spinal Muscular Atrophies Childhood</mesh_term>
	<criteria>Six nine month age young ( depend cohort ) day vector infusion Type 1 SMA define follow feature : Diagnosis SMA base gene mutation analysis biallelic SMN1 mutation ( deletion point mutation ) 2 copy SMN2 . Onset disease birth 6 month age . Hypotonia clinical evaluation delay motor skill , poor head control , round shoulder posture hypermobility joint . Active viral infection ( include HIV serology positive hepatitis B C ) Use invasive ventilatory support ( tracheotomy positive pressure ) * pulse oximetry &lt; 95 % saturation . Patients may put noninvasive ventilator support ( BiPAP ) less 16 hour day discretion physician research staff . Concomitant illness opinion PI create unnecessary risk gene transfer Concomitant use follow drug : drug treatment myopathy neuropathy , agent use treat diabetes mellitus , ongoing immunosuppressive therapy immunosuppressive therapy within 3 month start trial ( e.g . corticosteroid , cyclosporine , tacrolimus , methotrexate , cyclophosphamide , intravenous immunoglobulin , rituximab ) Patients AntiAAV9 antibody titer &gt; 1:50 determined ELISA bind immunoassay . Abnormal laboratory value consider clinically significant ( GGT &gt; 3XULN , bilirubin ≥ 3.0 mg/dL , creatinine ≥ 1.8 mg/dL , Hgb &lt; 8 &gt; 18 g/Dl ; WBC &gt; 20,000 per cmm ) Participation recent SMA treatment clinical trial opinion PI create unnecessary risk gene transfer . Family want disclose patient 's study participation primary care physician medical provider . Patient sign aspiration base swallow test unwilling use alternative method oral feeding . Patients single base substitution SMN2 ( c.859G &gt; C exon 7 ) exclude base predict mild phenotype .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Gene Transfer</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Adeno-associated virus</keyword>
	<keyword>Survival Motor Neuron</keyword>
	<keyword>SMN</keyword>
	<keyword>AAV9</keyword>
</DOC>